» Articles » PMID: 38958821

Ectonucleotidase Inhibitors: Targeting Signaling Pathways for Therapeutic Advancement-an In-depth Review

Overview
Publisher Springer
Date 2024 Jul 3
PMID 38958821
Authors
Affiliations
Soon will be listed here.
Abstract

Ectonucleotidase inhibitors are a family of pharmacological drugs that, by selectively targeting ectonucleotidases, are essential in altering purinergic signaling pathways. The hydrolysis of extracellular nucleotides and nucleosides is carried out by these enzymes, which include ectonucleoside triphosphate diphosphohydrolases (NTPDases) and ecto-5'-nucleotidase (CD73). Ectonucleotidase inhibitors can prevent the conversion of ATP and ADP into adenosine by blocking these enzymes and reduce extracellular adenosine. These molecules are essential for purinergic signaling, which is associated with a variability of physiological and pathological processes. By modifying extracellular nucleotide metabolism and improving purinergic signaling regulation, ectonucleotide pyrophosphatase/phosphodiesterase (ENPP) inhibitors have the potential to improve cancer treatment, inflammatory management, and immune response modulation. Purinergic signaling is affected by CD73 inhibitors because they prevent AMP from being converted to adenosine. These inhibitors are useful in cancer therapy and immunotherapy because they may improve chemotherapy effectiveness and alter immune responses. Purinergic signaling is controlled by NTPDase inhibitors, which specifically target enzymes involved in extracellular nucleotide breakdown. These inhibitors show promise in reducing immunological responses, thrombosis, and inflammation, perhaps assisting in the treatment of cardiovascular and autoimmune illnesses. Alkaline phosphatase (ALP) inhibitors alter the function of enzymes involved in dephosphorylation reactions, which has an impact on a variety of biological processes. By altering the body's phosphate levels, these inhibitors may be used to treat diseases including hyperphosphatemia and certain bone problems. This article provides a guide for researchers and clinicians looking to leverage the remedial capability of ectonucleotidase inhibitors in a variety of illness scenarios by illuminating their processes, advantages, and difficulties.

References
1.
Zimmermann H, Zebisch M, Strater N . Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal. 2012; 8(3):437-502. PMC: 3360096. DOI: 10.1007/s11302-012-9309-4. View

2.
Fredholm B, IJzerman A, Jacobson K, Klotz K, Linden J . International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001; 53(4):527-52. PMC: 9389454. View

3.
Fredholm B, IJzerman A, Jacobson K, Linden J, Muller C . International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. Pharmacol Rev. 2011; 63(1):1-34. PMC: 3061413. DOI: 10.1124/pr.110.003285. View

4.
Al-Rashida M, Qazi S, Batool N, Hameed A, Iqbal J . Ectonucleotidase inhibitors: a patent review (2011-2016). Expert Opin Ther Pat. 2017; 27(12):1291-1304. DOI: 10.1080/13543776.2017.1369958. View

5.
Gao Z, Jacobson K . Emerging adenosine receptor agonists. Expert Opin Emerg Drugs. 2007; 12(3):479-92. PMC: 11790296. DOI: 10.1517/14728214.12.3.479. View